<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>29029824</identifier>
<setSpec>1578-1968</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>González-Garza, M T</dc:author>
<dc:author>Escamilla-Ocañas, C E</dc:author>
<dc:author>Moreno-Cuevas, J</dc:author>
<dc:author>Martínez, H R</dc:author>
<dc:author>García Sarreón, M A</dc:author>
<dc:author>Camara-Lemarroy, C R</dc:author>
<dc:description xml:lang="en">INTRODUCTION Neuroinflammation has recently been described in amyotrophic lateral sclerosis (ALS). However, the precise role of such proinflammatory cytokines as monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1β (MIP-1β) in ALS has not yet been determined. In this study, we determined cerebrospinal fluid (CSF) MCP-1 and MIP-1β levels and assessed their association with the duration and severity of ALS. METHODS Concentrations of MCP-1 and MIP-1β were determined in the CSF of 77 patients diagnosed with ALS and 13 controls. Cytokine levels were analysed in relation to ALS duration (&lt;12months vs. &gt;12months) and severity (&lt;30points vs. &gt;30points on the ALS Functional Rating Scale administered at hospital admission). RESULTS Higher CSF MIP-1β (10.68pg/mL vs. 4.69pg/mL, P&lt;.0001) and MCP-1 (234.89pg/mL vs. 160.95pg/mL, P=.011) levels were found in the 77 patients with ALS compared to controls. There were no differences in levels of either cytokine in relation to disease duration or severity. However, we did observe a significant positive correlation between MIP-1β and MCP-1 in patients with ALS. CONCLUSIONS The increase in MIP-1β and MCP-1 levels suggests that these cytokines may have a synergistic effect on ALS pathogenesis. However, in our cohort, no association was found with either the duration or the clinical severity of the disease.</dc:description>
<dc:type>Journal Article</dc:type>
<dc:language>es</dc:language>
<dc:subject>Neuroinflamación</dc:subject>
<dc:subject>MCP-1</dc:subject>
<dc:subject>Biomarcador</dc:subject>
<dc:subject>Cytokines</dc:subject>
<dc:subject>MIP-1β</dc:subject>
<dc:subject>Esclerosis lateral amiotrófica (ELA)</dc:subject>
<dc:subject>Citoquinas</dc:subject>
<dc:subject>Biomarkers</dc:subject>
<dc:subject>Amyotrophic lateral sclerosis (ELA)</dc:subject>
<dc:subject>Neuroinflammation</dc:subject>
<dc:date>2017 Oct 10 </dc:date>
<dc:title xml:lang="es">Incremento de las citoquinas proteína quimiotáctica de monocitos-1 (MCP-1) y proteína inflamatoria macrofágica-1β (MIP-1β) en líquido cefalorraquídeo de pacientes con esclerosis lateral amiotrófica.</dc:title>
<dc:title xml:lang="en">Increased cerebrospinal fluid levels of cytokines monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1β (MIP-1β) in patients with amyotrophic lateral sclerosis.</dc:title>
<dc:publisher>Neurologia (Barcelona, Spain)</dc:publisher>
</metadata>
</record>
</pubmed-document>
